Expert Insights Into Identifying and Treating TRK Fusion Solid Tumors in Adults and Children
BALTIMORE, MD - Hilton Baltimore - Holiday Ballroom - 2nd floor
November 7, 2019 | 7:00 pm
    Activity Overview

    Optimizing testing for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions in appropriate adult and pediatric patients with solid tumors can identify those who may benefit from treatment with targeted TRK inhibitor therapy. Many pathologists and clinicians on the oncology care team may be unfamiliar with the clinical significance of NTRK gene fusions and with best practice diagnostic strategies for identifying TRK fusion solid tumors. In this interactive symposium, 2 pathologists and a medical oncologist will discuss the role and methods for NTRK fusion testing in select patients with solid tumors as well as clinical trial safety and efficacy data on available and emerging TRK inhibitors. The expert panel will also discuss strategies for improving communication between pathologists and medical oncologists to facilitate timely identification and treatment of patients with tumors harboring NTRK fusions.

    • Marilyn Li, MD
      Vice Chief
      Division of Genomic Diagnostics
      Cancer Genomic Diagnostics
      Children’s Hospital of Philadelphia
      Philadelphia, Pennsylvania
    • Anna Farago, MD, PhD
      Instructor, Medicine
      Harvard Medical School
      Assistant, Medicine
      Division of Hematology/Oncology
      Massachusetts General Hospital
      Boston, Massachusetts
    • Susan Hsiao, MD, PhD
      Assistant Professor
      Pathology & Cell Biology
      Columbia University Medical Center
      New York, New York
    Program Thursday, November 7, 2019
    • 7:00 PM
    • Dessert Reception
    • 7:30 PM
    • Welcome and Introductions
      Marilyn Li, MD
    • 7:35 PM
    • Overview of TRK Fusion Cancer
      Marilyn Li, MD
    • 7:45 PM
    • Evidence-Based Use of TRK Inhibitors in Practice
      Anna Farago, MD, PhD
    • 8:00 PM
    • Methods for Detecting TRK Fusion Cancers
      Susan Hsiao, MD, PhD
    • 8:15 PM
    • Best Practices for Communication With the Oncology Care Team
    • 8:25 PM
    • Summary and Concluding Remarks
      Marilyn Li, MD
    Learning Objectives
    • Have increased knowledge regarding the
      • Prevalence of NTRK gene fusions in both common and rare solid tumors
      • Safety and efficacy of TRK inhibitors in adult and pediatric patients whose tumors harbor an NTRK gene fusion
    • Have greater competence related to
      • Recognizing best practices for NTRK gene fusion testing to inform clinical decision making
      • Identifying appropriate patients for NTRK gene fusion testing
    Target Audience
    Goal Statement
    Credits Available
    • 1.0
    • For Physicians
    Accreditation Statement
    Hilton Baltimore
    Holiday Ballroom - 2nd floor
    Developed through the strategic partnership between the Association for Molecular Pathology (AMP) and Medscape.
    Supported by an independent educational grant from